Although some targeted molecules commonly used in clinical practice, such as mTOR inhibitors (temsirolimus) and VEGF (bevacizumab), have been proven to be effective in RCC [2, 3], the emergence of drug resistance still leads to an unsatisfactory prognosis of RCC [4]. This evidence concerns the gene VEGFA and renal cell carcinoma.